Rwanda & Moderna

Rwanda: Rwanda>>> has closed its land border with the Democratic Republic of the Congo>>> as a precautionary measure against the spread of Ebola.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

Rwanda: Rwanda has been implicated in backing the March 23 Movement, which controls areas affected by the Ebola outbreak, and has closed its borders to the Democratic Republic of the Congo.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Rwanda: At risk of cross-border spread, with WHO training healthcare workers. Its preparedness is crucial to prevent a regional escalation.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

Rwanda: Rwanda has been mentioned in the context of border restrictions with the Democratic Republic of the Congo to prevent the spread of Ebola, and its alleged backing of the March 23 Movement rebel group.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Rwanda: Neighboring country at risk, mentioned in context of border conflict.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.